ARGENX SE annual report, Q4 FY2020

Business context and reporting period

argenx SE’s Form 20-F is an audited annual report for the fiscal year ended December 31, 2020, prepared under IFRS as issued by the IASB. It is not a standalone fourth-quarter report; the filing does not provide clear Q4-only financial results. argenx is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer. It had no approved products and no product-sales revenue during 2020.

Key financial metrics

Amounts are in euros unless indicated. Financial results compare full-year 2020 with full-year 2019.

There were no financial borrowings at December 31, 2020. Total liabilities include deferred revenue, not just amounts payable; current and non-current deferred revenue totaled €257.0 million. The filing does not present a conventional operating margin, and the company reported substantial operating and net losses.

Material changes versus the prior comparable period

• Revenue fell 48%, chiefly because 2019 included a €26.6 million AbbVie milestone recognized after the first-in-human trial of ABBV-151 and higher Janssen research and development cost reimbursements. In 2020, increased recognition of Janssen upfront consideration partly offset the decline.
• Research and development expense rose 65%, primarily as efgartigimod clinical and manufacturing activity expanded; external R&D expense for that program increased to €160.4 million from €84.2 million.
• Selling, general and administrative expense rose 131%, reflecting increased staffing, share-based compensation and preparation for a potential U.S. product launch.
• The net loss more than tripled. In addition to higher operating expenses, 2020 included €107.0 million of exchange losses, compared with €6.1 million of exchange gains in 2019, mainly from translating U.S.-dollar cash and investments into euros.
• Operating cash flow shifted to a substantial outflow, as clinical development, launch preparation and pre-launch inventory costs replaced the prior year’s substantial Janssen upfront cash receipt. Financing cash inflow was €747.9 million, largely from 2020 equity offerings.

Outlook, management commentary, risks and unusual items

• Pipeline and regulatory: argenx reported positive topline Phase 3 ADAPT results for intravenous efgartigimod in generalized myasthenia gravis (gMG) and submitted a U.S. BLA in December 2020. The filing, signed March 30, 2021, reports subsequent acceptance of the BLA and a December 17, 2021 FDA action date. Those are post-year-end developments, not 2020 results.
• Other programs: efgartigimod was being advanced in ITP, pemphigus vulgaris and CIDP, with additional indications planned. Cusatuzumab development continued with Janssen; the filing describes subsequent January 2021 interim CULMINATE results. These programs remained subject to clinical and regulatory uncertainty.
• Outlook and funding: management expected 2021 cash burn to increase significantly to support commercial infrastructure, drug inventory, clinical programs and research. Based on its assumptions, the company said year-end 2020 cash, cash equivalents and current financial assets were expected to fund operating expenses and capital expenditure for at least the next 12 months. It also stated that additional funding would be required in the future; availability and terms were uncertain.
• Subsequent financing and partnership: after year-end, argenx entered a Greater China efgartigimod license agreement with Zai Lab, with up to $175 million in collaboration payments and potential royalties. A February 2021 equity offering generated reported net cash proceeds of €908.0 million. Neither was included in year-end 2020 liquidity.
• Unusual item: in November 2020, the company agreed to acquire an FDA Priority Review Voucher for $98 million, intending to use it for a future efgartigimod application, not the gMG BLA. The filing reports €80.7 million in additions to other intangible assets in 2020.
• Risks: principal exposures include clinical-trial failure or delay, regulatory approval and commercialization risk, payer access and pricing, reliance on third-party manufacturers and research organizations, intellectual-property challenges, competition, and COVID-19 disruption. The company also had significant U.S.-dollar exposure and no currency hedging arrangements. Management reported limited COVID-19 impact to date but said effects on trials, operations and partners remained uncertain.
• Contingencies and controls: the company reported no current material litigation or claims. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The auditor identified R&D accrual estimation as a critical audit matter; €52.6 million of clinical and manufacturing accruals depended on estimates of vendor progress.

Most important facts an investor should verify

• Confirm current regulatory status, labeling, launch timing and commercial uptake of efgartigimod; distinguish 2020 disclosures from the filing’s subsequent 2021 updates.
• Track cash burn, operating cash flow and remaining liquidity, including how the 2021 financing and Zai Lab proceeds were received and deployed.
• Review the size, timing and outcomes of efgartigimod trials across indications and the cusatuzumab program, including safety findings and any changes to development plans.
• Assess the impact of the euro/U.S.-dollar exchange rate on reported results and the value and liquidity of cash and financial assets.
• Examine the assumptions behind R&D accruals, pre-launch inventory recoverability, the Priority Review Voucher asset and collaboration revenue recognition.